KAROLINSKA INSTITUTET INNOVATIONS AB

Their core work

Karolinska Institutet Innovations AB is the technology transfer and commercialization office of Karolinska Institutet, one of the world's leading medical universities and the institution that awards the Nobel Prize in Physiology or Medicine. Their core work is turning biomedical research into licensed intellectual property, spin-off companies, and commercial partnerships — bridging the gap between academic discovery and market application. In H2020, they contributed to building an EU-wide health innovation marketplace (UTILE) and supported an ERC Proof of Concept project on antiviral therapy targeting DNA repair mechanisms (NOVITREP). For any organization seeking to access or commercialize life sciences research from a top-tier academic environment, they are the gateway into Karolinska's research pipeline.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2017, meaning there is no temporal shift to analyze within the available data — the organization's profile is a snapshot of a single moment rather than an arc. No keyword data was present in either project, which further limits any trend inference. What can be observed is that even in this narrow window, they operated at two levels simultaneously: building EU-level infrastructure for health research valorization (UTILE, CSA) and executing hands-on translational support for a specific scientific breakthrough (NOVITREP, ERC-POC) — a pattern consistent with a mature technology transfer office rather than a narrowly specialized unit.

With only two projects from the same year and no keyword evolution data, no directional shift can be reliably identified — future collaborators should assess their current portfolio directly through their website rather than projecting from H2020 history.

How they like to work

Karolinska Institutet Innovations AB participates exclusively as a consortium partner — they have never taken on a coordinator role in H2020. Despite only two projects, they engaged with 13 unique partners across 8 countries, suggesting they plug into broad, internationally distributed consortia rather than tight bilateral arrangements. This pattern is typical for a technology transfer office: they contribute specialized IP and commercialization expertise to consortia that need a credible translation pathway, rather than driving research agendas themselves.

Across two projects, they connected with 13 unique partners spanning 8 countries — a notably wide reach for such a small H2020 footprint, likely reflecting the pan-European character of both consortia (particularly UTILE as a coordination action). No evidence of repeated partnerships within this dataset.

What sets them apart

Karolinska Institutet Innovations AB sits at the heart of one of the most productive biomedical research ecosystems in Europe — the same institution that houses the Nobel Assembly for Physiology or Medicine. This is not a generic technology transfer office: access to their pipeline means access to research that is routinely among the most cited in clinical medicine globally. For businesses or consortia seeking credible health research commercialization expertise with genuine proximity to breakthrough science, few European TTOs carry equivalent institutional weight.

Highlights from their portfolio

• UTILE
  Highest-funded project (EUR 175,846) and a pan-European coordination action to build a shared valorization marketplace for all FP7 Health and H2020 SC1 outputs — a strategic infrastructure role well beyond typical participant contributions.
• NOVITREP
  An ERC Proof of Concept grant targeting novel antiviral therapy through DNA repair inhibition — the most scientifically specific project in their portfolio and a direct example of translating a Karolinska ERC award toward commercial application.